非肌层浸润性膀胱癌新型膀胱内治疗的系统综述
该系统综述检索2020至2024年文献,评估新型膀胱内治疗对非肌层浸润性膀胱癌的疗效与安全性。纳入36项报告疗效与安全性的临床试验,显示初治患者初始应答率65%至100%,BCG无应答/难治患者为42%至85%,严重毒性少见,但研究多为早期且异质性大。
要点
- 新型膀胱内治疗在BCG无应答和初治NMIBC中均显示有前景的初始应答率。
- 12个月无复发生存率在BCG无应答患者为22%至83%,初治患者为39%至92%。
- 疾病进展和严重毒性(≥3级)罕见,患者报告结局稳定。
核心结论
- 新型膀胱内治疗对NMIBC显示出有前景的疗效和耐受性,但需进一步研究长期结局、生活质量和经济因素。
研究设计与样本
- 系统综述,检索2020至2024年发表的临床试验,共纳入2998项研究中的36项报告疗效与安全性,6项提供患者报告结局。
- 因比较数据有限,未进行统计合成。
主要发现
- BCG无应答/难治患者的初始应答率为42%至85%,初治患者为65%至100%。
- BCG无应答/难治患者的12个月无复发生存率为22%至83%,初治患者为39%至92%。
- 疾病进展和严重毒性(≥3级)罕见,分别为0至17%和0至20%。
- 患者报告结局稳定。
关键数值与推荐
- 膀胱内治疗包括基于BCG的疗法、化疗联合方案、化学药物偶联物、热凝胶、热灌注化疗、渗透泵和基因治疗。
临床怎么用
- 新型膀胱内治疗可作为NMIBC尤其是BCG无应答患者的潜在选择,但需结合早期研究证据谨慎评估。
局限性
- 研究多为早期阶段,结局评估异质性大。
- 需要长期耐久性、比较有效性、生活质量和成本方面的研究。
- 未来研究应采用多臂多阶段设计并关注以患者为中心的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Intravesical therapy is central to managing non-muscle-invasive bladder cancer (NMIBC); yet, recurrence and progression remain common, underscoring the need for new treatments. This systematic review evaluates clinical trials of novel intravesical therapies for all risk categories of NMIBC. METHODS: A comprehensive literature search was conducted to identify the clinical trials assessing the effectiveness, safety, and tolerability of intravesical therapies for NMIBC. The search focused on studies published from 2020 to 2024, including trials on bacillus Calmette-Guérin (BCG)-unresponsive/refractory disease as well as on BCG-naïve and intermediate-risk patients. Mechanisms of action and drug delivery methods were summarized. No statistical syntheses were performed due to limited comparative data. KEY FINDINGS AND LIMITATIONS: Out of 2998 studies identified, 36 reported on efficacy and safety, and six provided patient-reported outcomes (PROs). Intravesical therapies included BCG-based therapies, chemotherapy combinations, chemical-drug conjugates, thermogels, hyperthermic chemotherapy, osmotic pumps, and gene therapy. Initial response rates ranged from 42% to 85% for BCG-unresponsive/refractory patients and from 65% to 100% for treatment-naïve patients. The 12-mo recurrence-free survival rates ranged from 22% to 83% and 39% to 92%, respectively. Progression and severe toxicity (grade ≥3) were rare (0-17% and 0-20%, respectively). PROs were stable. The limitations included early-phase studies, heterogeneous outcome assessments, and a need for research on long-term durability, comparative effectiveness, quality of life, and cost. CONCLUSIONS AND CLINICAL IMPLICATIONS: This systematic review highlights the promising efficacy and tolerability of novel intravesical therapies for NMIBC. However, further research is needed to refine treatment strategies and assess long-term outcomes, quality of life, and economic factors. Future studies should include multiarm, multistage designs with a focus on patient-centered outcomes.
引用
- Ghodoussipour S, Bivalacqua T, Bryan RT, et al. A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer. Eur Urol. 2025. PMID: 40253283. doi:10.1016/j.eururo.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。